CagnolSRivardN. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2), resulting in nuclear ERK1/2 inhibition. Oncogene. 2013;32(5v):564-576. doi:10.1038/onc.2012.88.
2.
MolinaJRAdjeiAA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006;1(1):7-9.
3.
RauenKA. The RASopathies. Annu Rev Genomics Hum Genet. 2013;14:355-369. doi:10.1146/annurev-genom-091212-153523.
4.
KangMLeeYS. The impact of RASopathy-associated mutations on CNS development in mice and humans. Mol Brain. 2019;12(1):96. doi:10.1186/s13041-019-0517-5.
5.
RobertsAE. Noonan syndrome. In: AdamMPArdingerHHPagonRA, et al, eds. GeneReviews®. Seattle, WA: University of Washington; 1993.
6.
BhambhaniVMuenkeM. Noonan syndrome. Am Fam Physician. 2014;89(1):37-43.
7.
NagatomoKFukushimaHKanaiYMuramatsuHTakadaH. A neonate diagnosed with Noonan syndrome with myeloproliferative change. Pediatr Int. 2021;63(12):1521-1523. doi:10.1111/ped.14634.
8.
TartagliaMGelbBDZenkerM. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25(1):161-179. doi:10.1016/j.beem.2010.09.002.
9.
StrulluMCayeALachenaudJ, et al. Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet. 2014;51(10):689-697. doi:10.1136/jmedgenet-2014-102611.
10.
LipkaDBWitteTTothR, et al. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2126. doi:10.1038/s41467-017-02177-w.
11.
GuptaAKMeenaJPChopraATanwarPSethR. Juvenile myelomonocytic leukemia-a comprehensive review and recent advances in management. Am J Blood Res. 2021;11(1):1-21.
12.
BastidaPGarcía-MiñaúrSEzquietaBDapenaJLSanchez de ToledoJ. Myeloproliferative disorder in Noonan syndrome. J Pediatr Hematol Oncol. 2011;33(1):e43-e45. doi:10.1097/MPH.0b013e3181e7571e.
13.
ChanRJCooperTKratzCPWeissBLohML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355-362. doi:10.1016/j.leukres.2008.08.022.
14.
ArberDAOraziAHasserjianR, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544.
15.
WajidM AGuptaAKDasGSahooDMeenaJPSethR. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine. Pediatr Hematol Oncol. 2020;37(7):573-581. doi:10.1080/08880018.2020.1767244.
